ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Coronary Disease - Other

July 11, 2022
There could be some translational value for cardiovascular surgical practice from this prospective cardiovascular health study. The mechanistic link warrants further investigation and interpretation.
June 23, 2022
This scientific statement is a granular contribution to a major cardiovascular issue, illuminating nuances of the "generally recognized as safe" (GRAS) FDA designation. One would expect the relevant Thoracic Associations in North America and Europe to contribute to this debate.
April 19, 2022
Interesting manuscript on the immunology of coronary atheroma, with tanslational potential in therapies and prevention of ischaemic heart disease.
December 25, 2021
The rising burden of CAD in low- and middle-income countries like Nigeria is a result of the epidemiological transition from communicable to non- communicable diseases. The system of care for acute coronary syndrome (ACS) is evolving and constrained by a lack of prehospital emergency services, prolonged intervention times, and low patient eligibility
November 15, 2021
Interesting in its candour mini-series of partial arterial revascularisation by left thoracotomy. The perioperative graft failure is delt in some detail.
November 9, 2021
A good-size Terumo-sponsored RCT that is set to impact on decisions to discontinue DAPT early after PCI with absorbable stent, a change that will somehow decrease the surgical risk of bleeding in the event of salvage CABG. 
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.
June 15, 2021
Fascinating confirmation of null hypotheses including bleeding complications and survival in a Pennsylvanian cohort study, despite the easily predictable previous PCI, hock, and IABP prevalence in the emergency group. The statistical model is elaborate and complex. Perhaps a randomized trial could now be justified!
May 27, 2021
This month's update on the economical and general aspects of the ROOBY-FS trial. The conclusion (on no impact of de novo post-CABG AF on the incidence of stroke nor the 5 year expenditure ) challenges many hitherto perceptions on this frequent compication of coronary surgery.
February 21, 2021
An editorial that may herald the decrease in aspirinization and the rise of ticagrelor monotherapy in Percutaneous stenting of coronary arteries.

Pages